Tarsus Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Tarsus Pharmaceuticals
TARS Stock  USD 68.11  0.25  0.37%   
Tarsus Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Tarsus Pharmaceuticals' valuation are provided below:
Gross Profit
278.3 M
Profit Margin
(0.22)
Market Capitalization
2.9 B
Enterprise Value Revenue
7.0263
Revenue
366.1 M
There are over one hundred nineteen available fundamental trend indicators for Tarsus Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should double-check Tarsus Pharmaceuticals' current fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 2 B in 2026. Enterprise Value is likely to gain to about 1.9 B in 2026

Tarsus Pharmaceuticals Total Revenue

220.92 Million

Check Tarsus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tarsus Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 8.7 M or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 13.51, Dividend Yield of 0.0 or PTB Ratio of 8.76. Tarsus financial statements analysis is a perfect complement when working with Tarsus Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Tarsus Stock
Check out the analysis of Tarsus Pharmaceuticals Correlation against competitors.
For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.

Tarsus Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets455.2 M433.5 M128.8 M
Slightly volatile
Other Current Liabilities63.1 M60.1 M12.6 M
Slightly volatile
Total Current Liabilities97.3 M92.7 M20.1 M
Slightly volatile
Property Plant And Equipment Net1.7 M3.3 M952 K
Slightly volatile
Accounts Payable33.5 M31.9 M7.3 M
Slightly volatile
Cash124.3 M109 M61.4 M
Slightly volatile
Non Current Assets Total24.5 M23.3 M5 M
Slightly volatile
Cash And Short Term Investments178.5 M335.1 M98.1 M
Slightly volatile
Net Receivables58 M55.3 M10.8 M
Slightly volatile
Common Stock Total Equity3.5 K5.8 K2.5 K
Slightly volatile
Common Stock Shares Outstanding24.6 M43.2 M15.2 M
Slightly volatile
Liabilities And Stockholders Equity455.2 M433.5 M128.8 M
Slightly volatile
Non Current Liabilities Total86.8 M82.6 M22.9 M
Slightly volatile
Other Current Assets17.7 M16.8 M4 M
Slightly volatile
Total Liabilities184.1 M175.3 M43 M
Slightly volatile
Property Plant And Equipment Gross5.8 M5.6 M1.4 M
Slightly volatile
Total Current Assets430.7 M410.2 M123.8 M
Slightly volatile
Capital Stock4.2 K6.9 K2.7 K
Slightly volatile
Net Working Capital172 M317.5 M94.2 M
Slightly volatile
Common Stock4.2 K6.9 K2.7 K
Slightly volatile
Property Plant Equipment711.5 K1.1 M412.2 K
Slightly volatile
Short and Long Term Debt Total87.5 M83.3 M17.5 M
Slightly volatile
Non Currrent Assets Other7.4 M7 M1.4 M
Slightly volatile
Other Assets0.860.987.3 K
Pretty Stable
Inventory2.2 M2.4 M21.6 M
Pretty Stable
Short Term Debt619.5 K699.2 K310.2 K
Slightly volatile
Other Liabilities58.1 K43.2 K57.4 K
Very volatile
Capital Surpluse261.8 M347 M230.3 M
Slightly volatile
Non Current Liabilities Other2.1 M2 M886.5 K
Slightly volatile
Current Deferred Revenue557.6 K627.3 K684.7 K
Slightly volatile
Long Term Debt44.4 M82.6 M28.3 M
Slightly volatile
Intangible Assets6.7 M9.6 M4.6 M
Slightly volatile

Tarsus Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.5 M1.4 M350.4 K
Slightly volatile
Selling General Administrative286.6 M272.9 M56.5 M
Slightly volatile
Other Operating Expenses366.5 M349.1 M81.2 M
Slightly volatile
Research Development33.1 M61.4 M18.4 M
Slightly volatile
Cost Of Revenue15.5 M14.7 M2.8 M
Slightly volatile
Total Operating Expenses351 M334.3 M78.4 M
Slightly volatile
Reconciled Depreciation1.5 M1.4 M335.7 K
Slightly volatile
Interest Income18.1 M17.3 M3.9 M
Slightly volatile

Tarsus Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation33.6 M32 M8 M
Slightly volatile
Begin Period Cash Flow271.6 M258.7 M72.2 M
Slightly volatile
Depreciation1.5 M1.4 M339.3 K
Slightly volatile
Capital Expenditures1.4 M1.8 M708.2 K
Slightly volatile
Issuance Of Capital Stock87.4 M113 M46.2 M
Slightly volatile
Total Cash From Financing Activities90.1 M177.9 M51.2 M
Slightly volatile
End Period Cash Flow124.7 M112 M61.7 M
Slightly volatile
Change To Netincome16.9 M16.1 M5.5 M
Slightly volatile
Change To Liabilities2.8 M4 M1.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.5110.2410.6195
Slightly volatile
Days Sales Outstanding10486.2942.0004
Slightly volatile
Stock Based Compensation To Revenue0.130.140.227
Slightly volatile
Capex To Depreciation1.41.473.8768
Slightly volatile
EV To Sales10.2610.137.5435
Slightly volatile
Inventory Turnover4.634.411.242
Slightly volatile
Days Of Inventory On Hand81.4685.74600
Slightly volatile
Payables Turnover0.440.420.1551
Slightly volatile
Sales General And Administrative To Revenue0.871.570.7652
Slightly volatile
Research And Ddevelopement To Revenue0.320.340.8391
Pretty Stable
Capex To Revenue0.00730.00770.0283
Pretty Stable
Cash Per Share5.086.973.5825
Slightly volatile
Days Payables Outstanding8629082.1 K
Slightly volatile
Intangibles To Total Assets0.01460.01990.0153
Slightly volatile
Net Debt To EBITDA0.230.242.9816
Very volatile
Current Ratio4.835.0916.0921
Very volatile
Receivables Turnover4.164.38439
Slightly volatile
Capex Per Share0.03550.03750.0234
Slightly volatile
Revenue Per Share4.64.382.8695
Pretty Stable
Interest Debt Per Share2.011.910.4902
Slightly volatile
Debt To Assets0.180.170.0464
Slightly volatile
Operating Cycle261153101
Slightly volatile
Days Of Payables Outstanding8629082.1 K
Slightly volatile
Ebt Per Ebit1.111.11.0063
Slightly volatile
Long Term Debt To Capitalization0.130.220.1126
Slightly volatile
Quick Ratio4.85.0516.0811
Very volatile
Net Income Per E B T0.80.90.983
Slightly volatile
Cash Ratio1.291.3514.6974
Pretty Stable
Days Of Inventory Outstanding81.4685.74600
Slightly volatile
Days Of Sales Outstanding10486.2942.0004
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.920.986
Slightly volatile
Fixed Asset Turnover60.3257.4533.9894
Slightly volatile
Debt Ratio0.180.170.0464
Slightly volatile
Price Sales Ratio13.5110.2410.6195
Slightly volatile
Asset Turnover0.460.440.317
Pretty Stable
Gross Profit Margin1.031.070.9685
Slightly volatile

Tarsus Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2 B1.9 B835.6 M
Slightly volatile
Enterprise Value1.9 B1.9 B813.4 M
Slightly volatile

Tarsus Fundamental Market Drivers

Forward Price Earnings116.2791
Cash And Short Term Investments291.4 M

Tarsus Upcoming Events

11th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
11th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tarsus Pharmaceuticals Financial Statements

Tarsus Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Tarsus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tarsus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tarsus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue627.3 K557.6 K
Total Revenue210.4 M220.9 M
Cost Of Revenue14.7 M15.5 M
Stock Based Compensation To Revenue 0.14  0.13 
Sales General And Administrative To Revenue 1.57  0.87 
Research And Ddevelopement To Revenue 0.34  0.32 
Capex To Revenue 0.01  0.01 
Revenue Per Share 4.38  4.60 
Ebit Per Revenue(0.76)(0.80)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY